ANAntje Frey Nascimento

Antje Frey Nascimento

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antje Frey Nascimento has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Jens Gaab

    Division of Clinical Psychology and Psychotherapy, Faculty of Psychology, University of Basel, Basel, Switzerland

    8 shared publications
  • Cosima Locher

    Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    6 shared publications
  • Joe Kossowsky

    Department of Anesthesiology, Critical Care & Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

    4 shared publications
  • Andrea Meyer

    Division of Clinical Psychology and Epidemiology, Department of Psychology, University of Basel, Basel, Switzerland

    3 shared publications
  • Charlotte Blease

    Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden

    3 shared publications
  • Irving Kirsch

    Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    3 shared publications

Latest Publications

  • Open Access

    Generative AI Adoption in Psychotherapy Practice Among Mental Health Professionals: Multicountry Cross-Sectional Survey

    by Charlotte Blease, Josefin Hagström, Jens Gaab, Alexis Carey, Francesco Cipriani, Colin Gorman, Antje Frey Nascimento, Amanda Fitzgerald, Lena Holtz, Julian Schwarz, et al.

    Background: Generative AI (GenAI) tools, such as OpenAI’s ChatGPT, Google’s Gemini, and Microsoft Copilot, are being adopted across health care settings. Despite the popularity of GenAI, empirical data on the extent of adoption by mental health clinicians in routine psychotherapy practice are scarce. Objective: This study aimed to characterize purposeful GenAI use among mental health professionals providing psychotherapy, including tools used, purposes, perceived workload effects, and the organizational context surrounding use. Methods: We conducted a cross-sectional online survey between January 13, 2026, and March 30, 2026. A convenience sample of trained mental health professionals who had provided psychotherapy within the previous 12 months was recruited through professional associations and academic and clinical mailing lists, with snowball dissemination by email. The survey assessed lifetime purposeful GenAI use in psychotherapy practice; tools and purposes of use; perceived work burden reduction; and, for the previous 12 months, employer or professional organization encouragement, prohibition, and participation in AI training. Descriptive statistics were calculated. Univariable logistic regression models were used to examine associations between GenAI use and candidate factors. Variables meeting an entry criterion of P<.10 were entered into a multivariable logistic regression; statistical significance was set at P<.05. Results: A total of 766 mental health professionals who provide psychotherapy in 30 countries completed the survey. Of these, 54.6% (n=418, 95% CI 51.0%-58.1%) reported having purposely used at least 1 GenAI tool in clinical psychotherapy practice. ChatGPT was the most frequently used tool (354/418, 84.7%, 95% CI 81.2%-88.2%). The most commonly reported clinical purpose was assisting with treatment planning (175/418, 41.9%, 95% CI 37.1%-46.7%), followed by managing administrative tasks (n=173, 41.4%, 95% CI 36.6%-46.1%) and generating psychoeducational materials for clients (n=166, 39.7%, 95% CI 35.0%-44.4%). Among AI users, 82.8% (346/418, 95% CI 79.1%-86.4%) reported that these tools reduced their overall work burden. Only 18.1% (139/766, 95% CI 15.4%-20.9%) of respondents reported institutional encouragement to use GenAI tools, while 81.1% (n=621, 95% CI 78.3%-83.9%) reported not having received any professional training on AI use. In multivariable logistic regression (α=.05), younger age was associated with GenAI use, while practice setting showed mixed evidence of association. The overall adjusted effect of practice setting did not reach statistical significance (P=.07), although urban practitioners had lower odds of GenAI use than rural practitioners (adjusted odds ratio 0.614, 95% CI 0.388-0.971; P=.04). Conclusions: This study extends previous predominantly national and profession-specific research by providing a multicountry, multiprofessional snapshot of reported GenAI use in psychotherapy practice. Use extended beyond administrative tasks into clinically consequential activities, including treatment planning and psychoeducation, while participation in professional AI training remained relatively uncommon. Findings highlight the need for professional bodies, health systems, and training programs to develop practical guidance and competencies for safe, privacy-conscious, and clinically appropriate GenAI use.

  • Open Access

    Comparative efficacy and safety of oral pharmacological and complementary interventions for premenstrual syndrome: a protocol for a systematic review and a network meta-analysis

    by Bojana Degen, Cosima Locher, Helen Koechlin, Jens Gaab, Antje Frey Nascimento

    Background: Premenstrual syndrome (PMS) affects around 48% of women of reproductive age worldwide, interfering with psychological and physical well-being as well as functioning. A multitude of interventions exists for PMS, including oral pharmacological interventions, such as antidepressants, combined oral contraceptives, or alternative and complementary interventions. While the use of pharmacological interventions for PMS is linked to multiple side effects, evidence is limited for complementary interventions. Further, placebo effects are high in PMS intervention studies, affecting the estimation of the true treatment effect. An analysis of the relative efficacy between different treatment options is currently lacking, yet urgently needed for clinical decision-making. Methods: We plan a network meta-analysis to compare the relative efficacy and safety of oral pharmacological and non-pharmacological interventions for PMS, including all available randomized controlled trials, such as comparator or placebo-controlled trials. Primary outcomes will be symptom intensity and interference; secondary outcomes will be psychological and somatic symptom intensity. Safety will be assessed by the proportion of patients reporting treatment-related adverse events, unwanted events, and by dropouts due to side effects. Published trials will be retrieved from online electronic databases. At least two independent reviewers will screen, select references, and extract data independently. Risk of Bias will be assessed using the Cochrane risk of bias assessment 2 (RoB2) tool. We will conduct a random-effect network meta-analysis within a frequentist framework for each outcome to synthesize all available evidence and compare and rank available oral treatments. Discussion: Several interventions are available for PMS, a disabling condition that affects a large proportion of women worldwide. To our knowledge, this will be the first network meta-analysis to synthesize the existing evidence of oral PMS interventions systematically. Comparing the efficacy and safety of all available interventions is necessary to inform clinicians, patients and clinical guidelines to elect the best treatment regimen. Systematic review registration: PROSPERO CRD42020214716.

  • Open Access

    Generative Artificial Intelligence in Psychotherapy Practice: A Global Online Survey of Mental Health Professionals’ Adoption (Preprint)

    by Charlotte Blease, Josefin Hagström, Jens Gaab, Alexis Carey, Francesco Cipriani, Colin Gorman, Antje Frey Nascimento, Amanda Fitzgerald, Lena Holtz, Julian Schwarz, et al.

    BACKGROUND Generative artificial intelligence (GenAI) tools, including large language model (LLM)-based platforms such as ChatGPT, Google Gemini, and Microsoft Copilot, are being adopted across healthcare settings with increasing speed. Despite the increasing popularity of GenAI, empirical data on the extent and nature of adoption by mental health clinicians in routine psychotherapy practice globally remain scarce. OBJECTIVE This study aimed to characterize current use patterns of GenAI tools among a global sample of practicing mental health professionals, including prevalence of use, specific tools employed, clinical and administrative purposes served, perceived effect on workload, and the institutional context shaping adoption (e.g., encouragement, prohibition, and training). METHODS We administered a cross-sectional online survey to a global convenience sample of licensed mental health professionals who provide psychotherapy as part of the scope of their practice (i.e., psychotherapists, psychologists, counsellors, nurses, and psychiatrists). Participants were recruited via professional networks, purposely avoiding the use of social media platforms. Within the survey, we captured GenAI use behaviors in psychotherapy contexts, and demographic and professional background data. Descriptive statistics were analyzed for all variables. Multivariate logistic regression was used to examine demographic and professional predictors of GenAI use. RESULTS A total of 766 mental health professionals who provide psychotherapy from 30 countries completed the survey. Of these, 54.6% (n=418) reported having purposely used at least one GenAI tool in psychotherapy clinical practice. ChatGPT was the most frequently used tool (354/418, 84.7%). The most commonly reported clinical purpose was assisting with treatment planning (175/418, 41.9%), followed by managing administrative tasks (173/418, 41.4%) and generating psychoeducational materials for clients (166/418, 39.7%). 82.8% of AI users reported that these tools reduced their overall work burden. Only 18.1% (139/766) of respondents reported institutional encouragement to use AI tools, while 81.1% (621/766) reported not having received any professional training on AI use. Predictors of AI adoption included younger age and rural practice setting. CONCLUSIONS In this global convenience sample survey, GenAI use among mental health professionals in psychotherapy settings is widespread, concentrated in a wide variety of clinical and administrative tasks. Formal training and institutional guidance substantially lag behind current adoption patterns. These findings highlight an urgent need for evidence-based competency frameworks, regulatory clarity, and professional education to support safe and ethically informed integration of AI into clinical mental health practice.

  • Open Access

    Talking placebo: a qualitative study of patients’ attitudes toward open-label placebo implementation into clinical practice

    by Antje Frey Nascimento, Berfin Bakis, Jens Gaab, Tobias Schneider, Athina Papadopoulou, Milena Ritter, Michael H. Bernstein, Charlotte R. Blease, Cosima Locher

    Background: For more than a decade, studies have supported the efficacy and safety of placebos without deception—so-called open-label placebos (OLPs)—to harness placebo effects in primary care while aligning with key ethical principles. Since treatment acceptance, feasibility, and successful implementation of novel interventions into clinical practice depend on patients’ attitudes, patients’ perspectives, perceived obstacles, and ideas on OLP use in clinical practice have yet to be elucidated. Therefore, patient and public involvement is increasingly demanded in research and its implementation into clinical practice. Qualitative research offers a unique opportunity to comprehensively understand attitudes, expectations, perceived benefits, and barriers from a patient’s point of view. Thus, we studied patients’ attitudes, concerns, and ideas toward OLP implementation into clinical practice with focus group discussions (FGDs).Methods: In 2022, three exploratory online FGDs, each including two patients with the same condition, were conducted with adult patients affected by chronic back pain (n = 2), chronic migraine (n = 2), or chemotherapy-induced emesis/nausea (n = 2). Physicians recruited participants in three outpatient clinics at the University Hospital Basel in Switzerland. The FGDs were held online for 60 min. Qualitative data was analyzed using Reflexive Thematic Analysis, applying an inductive-deductive hybrid approach within a social constructivist framework.Results: In total, five semantic-latent subthemes were identified, entailing: (i) Placebos: Promising but risky; (ii) Acceptance of OLPs depends on a myriad; (iii) Be trustworthy, but deception may be necessary; (iv) Harnessing placebo effects without placebos; (v) From bench to bedside: Clinical transference of OLPs. The themes reflect an in-depth discussion of the usage of OLPs in the clinical context, accompanied by different ambivalences regarding implementation, prerequisites, and the provider role.Conclusion: The FGDs provided insights into distinct attitudes, concerns, varying acceptance, and patients’ ideas regarding the clinical implementation of OLP interventions. While some patients displayed high acceptance, several concerns regarding ethical and practical issues have been expressed. OLP acceptance and attitudes toward practical issues of OLP intake differed between groups and within the same clinical condition.Trail registration: ClinicalTrials.gov, identifier NCT05166213.


  • Open Access

    Conditioned open-label placebos to facilitate opioid reduction in patients with chronic non-cancer pain: study protocol of a randomised controlled trial

    by Katja Carratta, Kiara Bodonyi, Antje Frey Nascimento, Daniel Friis, Roland von Känel, Lukas Bircher, Helen Koechlin, Michael Bernstein, Konrad Streitberger, Isabelle Arnet, et al.

    Introduction Chronic non-cancer pain presents a global health problem, with a significant increase in opioid prescriptions over recent decades. However, opioid therapy poses risks of adverse events, overdose and non-medical use. As a result, many patients seek to discontinue or reduce their opioid intake. Strategies for opioid tapering often lack efficacy, prompting the investigation of novel approaches like open-label placebo (OLP), that is, the administration of a placebo with full disclosure that it is a placebo. OLP has shown efficacy in chronic non-cancer pain syndromes and has been suggested as a promising candidate for medication tapering. This study aims to assess whether OLPs can enhance the reduction of daily morphine equivalent dose (MED) in chronic non-cancer pain patients and examines its potential in mitigating opioid withdrawal symptoms. Methods and analysis This study is designed as a randomised, controlled, single-centre trial. Participants will be randomised into either an OLP group or a control group. The study duration will span six to nine weeks, during which all participants will aim to reduce their opioid intake. Both groups will monitor their opioid intake daily using a diary app and will receive feedback on their progress of reducing opioids. Additionally, participants in the OLP group will receive OLP tablets for the entire study period. During the first week, the OLP group will undergo a one week learning phase using a classical conditioning paradigm, where each opioid intake is paired with a placebo. In the subsequent five weeks, the OLP group will enter a dose-extension phase in which only the first opioid intake of the day is paired with a placebo, and additional placebos can be taken as desired. At the end of the study, qualitative interviews will be conducted with the first 15 participants in the OLP group. The primary outcome measure is daily opioid intake. Secondary outcomes include opioid withdrawal symptoms, pain severity, disability, anxiety, depression, opioid beliefs, intervention expectancy and qualitative data. Statistical analyses will include analysis of covariance and regression models. Ethics and dissemination The ethics committee of the Canton of Zurich, Switzerland, approved the study (SNCTP-nr.: SNCTP000005853/BASEC nr.: 2023–02327). Participants will be compensated with 100 Swiss Francs for their full participation in the study. Participants who will take part in the qualitative interview will be compensated with additional 15 Swiss Francs. Trial registration number This study is registered at clinicaltrials.gov: NCT06350786.


  • Open Access

    Efficacy of open-label placebos for premenstrual syndrome: a randomised controlled trial

    by Antje Frey Nascimento, Jens Gaab, Bojana Degen, Mareike Rytz, Anja Holder, Dilan Sezer, Sarah Buergler, Andrea H Meyer, Irving Kirsch, Joe Kossowsky, et al.

    Objective: To investigate the efficacy and safety of open-label placebos (OLP) in premenstrual syndrome (PMS).Design: Randomised controlled trial.Setting: Switzerland, 2018–2020.Participants: 150 women (18–45 years of age) with PMS or premenstrual dysphoric disorder.Intervention: Random assignment (1:1:1) to treatment as usual (TAU), OLP without treatment rationale (OLP–), or OLP with treatment rationale (OLP+). OLP consisted of two placebo pills per day for 6 weeks.Main outcome measures: Primary outcomes were PMS symptom intensity and interference between groups across three menstrual cycles (MC1–MC3); adverse events (ie, safety) were measured at weeks 3 and 6 after the start of the intervention. Secondary outcomes were psychological and somatic subscales of PMS symptom intensity, and adherence.Results: From 2 August 2018 to 3 December 2020, 150 women were randomly allocated to TAU (n=50), OLP– (n=50), and OLP+ (n=50), of whom 145 (96.7%) completed trial participation. Groups differed in symptom intensity (F(4)=4.419, p=0.002, r2=0.16) and interference (F(4)=3.159, p=0.014, r2=0.13) across three MCs. Mean symptom intensity at MC3 was lower for OLP+ compared to TAU (b=–9.97, SE=2.85, t(412)=3.50, p<0.001, d=0.90) and to OLP– (b=–6.10, SE=2.89, t(411)=2.11, p=0.036, d=0.55), but OLP– and TAU did not differ (b=–3.87, SE=2.87, t(411)=1.35, p=0.177, d=0.35). Mean interference at MC3 was lower for OLP+ compared to TAU (b=–1.23, SE=0.54, t(443)=2.30, p=0.022, d=0.55) and to OLP– (b=–1.10, SE=0.54, t(442)=2.02, p=0.044, d=0.48), but OLP– and TAU did not differ (b=–0.14, SE=0.54, t(442)=0.26, p=0.799, d=0.06). Four non-serious adverse events were reported in OLP– (n=1) and OLP+ (n=3). Improvement in psychological and somatic symptom intensity was comparable to primary outcomes. Adherence to the OLP intervention was high (93.18±18.95%), with no difference between groups.Conclusions: The results of our clinical trial indicate that OLP provided with a treatment rationale is an effective, safe, and acceptable treatment for PMS.Trial registration: ClinicalTrials.govNCT03547661(submitted 2 May 2018).


  • Open Access

    Lay perspectives of the open-label placebo rationale: a qualitative study of participants in an experimental trial

    by Cosima Locher, Sarah Buergler, Antje Frey Nascimento, Linda Kost, Charlotte Blease, Jens Gaab

    Objectives To analyse participants’ concepts about the open-label placebo (OLP) effect; to explore their views about the discussion points that are applied in conventional OLP trials and to examine their experiences of taking part in an OLP trial. Design A qualitative study using thematic analysis of semistructured interviews that were nested within a randomised controlled trial investigating experimental OLP analgesia (registered at ClinicalTrials.gov: NCT02578420). Participants 30 healthy adults who took part in the randomised controlled trial. Results Participants mostly conceptualised placebo as something that is inert and requires deception in order to be effective. Interviewees used a broad definition of placebos, going beyond a conventional notion of sugar pills. In contrast to the conventional OLP rationale, participants seldom emphasised classical conditioning as a mechanism of placebo effects, stressing a variety of other well-established components through which placebos might be therapeutic, whereas the conventional OLP disclosures state that ‘a positive attitude helps but is not necessary’, participants in our study applied other attitudes, such as ‘it’s worth a try’. When asked about their experiences during the trial, the majority emphasised that the concept of OLP was completely novel to them. Participants were rather sceptical about the efficacy of the intervention. Conclusion Integrating lay perspectives into the scientific rationale of OLP treatments might enhance the plausibility and credibility of the rationale in ethical treatments. Trial registration number NCT02578420.


  • Open Access

    Open-label placebo treatment of women with premenstrual syndrome: study protocol of a randomised controlled trial

    by Antje Frey Nascimento, Jens Gaab, Irving Kirsch, Joe Kossowsky, Andrea Meyer, Cosima Locher

    Introduction: Recent evidence suggests that for certain clinical conditions, placebos can improve clinical outcomes even without deception. These so-called open-label placebos (OLPs) bear the advantage of a significant lower risk of adverse events and comply with ethical principles. Although premenstrual syndrome (PMS) seems to be considerably susceptible to placebo effects, no study has examined open-OLP responses on PMS. Methods and analysis: To test the efficacy of OLPs in women suffering from PMS, a clinical randomised controlled trial including two OLP study groups (with and without treatment rationale) was designed to investigate on the effect on PMS. PMS symptoms are monitored on a daily basis via a symptom diary, adverse events are monitored intermittently. The study started in spring 2018 and patients will be included until a maximum of 150 participants are randomised. Besides the primary outcome PMS symptom intensity and interference, an array of further variables is assessed. Multilevel modelling will be used for data analyses. Ethics and dissemination: Ethics approval was obtained from the Ethics Committee Northwest and Central Switzerland. Results of the main analysis and of secondary analyses will be submitted for publication in peer-reviewed journals. Trial registration numbers: (1) ClinicalTrials.gov ( NCT03547661 ); (2) Swiss national registration (SNCTP000002809).


  • Oncologist recommendation matters!—Predictors of psycho‐oncological service uptake in oncology outpatients

    by Antje Frey Nascimento, Theresa Tondorf, Sacha I. Rothschild, Michael T. Koller, Christoph Rochlitz, Alexander Kiss, Rainer M. Schaefert, Gunther P. Meinlschmidt, Sabina Hunziker, Jens Gaab, et al.

    Objective: Highly distressed cancer patients often do not use psycho‐oncological services (POS). Research on predictors of POS uptake has mainly focused on patient‐related variables and less on communication variables, so we examined the link between patient‐oncologist communication (ie, talking about psychosocial distress, providing detailed information, and recommending POS) and POS uptake.Methods: We conducted a prospective, observational study in an Oncology Outpatient Clinic in Switzerland. Predictors (ie, patient‐related variables and patient's reports of the patient‐oncologist communication) were assessed via semistructured interviews, and information on outpatient POS uptake was assessed after 4 months. For statistical analysis, a multivariate logistic regression was performed.Results: Of 333 participants (mean age 61 years; 55% male; 54% distress thermometer ≥5), 77 (23%) had used POS during a 4‐month period. Patients who reported an oncologist‐recommended POS (odds ratio [OR] = 6.27, 95% confidence interval [CI] = 3.14‐12.85) and those who were not sure if they had received a recommendation (OR = 4.64, 95% CI = 1.83‐11.97) were more likely to attend POS than those who reported receiving no recommendation. Talking about psychosocial distress (OR = 0.74, 95% CI = 0.38‐1.46) and providing detailed information about POS did not predict POS uptake (OR = 1.06, 95% CI = 0.46‐2.38).Conclusions: Oncologists' expert recommendations to attend POS were strongly associated with patients' uptake of POS. The central role played by oncologists should be accounted for in stepped psycho‐oncological care when POS referral pathways are defined.